Peri Mets / MSS-CRC Immunotherapy Trial (Oncolytic Virus + anti-PDL1)

[DK37]

PERITONEAL MET PATIENTS:

I know there has been a lot of interest in the oncolytic virus + PD(L)1 inhibitor strategy after I recently signed up for the NCT02636036 trial. I also wanted to post this because peri mets can be resistant to chemotherapy.

It is one experimental strategy to try to convert a cold MSS tumor into a highly inflamed tumor which "looks more like" a MSI-high CRC or HPV+ tumor in that regard (all of which often respond to PD(L)1 inhibitors).

This new Oncolytic virus + PDL1 inhibitor trial is opening in January. Trial sites so far: NYC and Buffalo, NY. It is specifically recruiting CRC patients with peritoneal mets.

Their inclusion criteria on paper looks a bit strict (can you join after failing FOLFIRI or do you need to at least try TAS/Stivarga first?) but you can see how strictly they interpret it by presenting your medical situation and seeing what they say.

https://clinicaltrials.gov/ct2/show/NCT02963831

Cheers,
-DK37

[Maia]

This is an important one.

ONCOS-102 has been tried also in mesothelioma. Durvalumab is an anti PD-L1 (similar to atezolizumab).

Some literature: http://jitc.biomedcentral.com/articles/ ... -2-S3-P230 http://www.tandfonline.com/doi/full/10. ... J1ZUBAQDA= http://www.tandfonline.com/doi/full/10. ... RydWVAQEAw https://www.researchgate.net/profile/Lu ... 0a0e16.pdf

[Steph20021]

I'll be keeping this on my radar. Thank you.

[Maia]

Update today on the ONCOS-102 trial (NCT02963831) from Ludwig Institute:
"The study is not yet recruiting patients, but we hope that it will be opened in the next few months. We will have sites in New York City, Buffalo, NY and Miami, Florida."